Both journals are anchored in large scientific societies and serve basically the same medical , physical and biological community and at the same scientific level ; the two journals are in the most recent Impact Factor list ranked almost back to back , indicating an equal importance and contribution to science .
Radiotherapy and Oncology is more than a scientific journal , it also serves other purpose s such as facilitate education through ( educational ) review s and improving the st and ard of care by bringing forward guidelines for conduct of radiotherapy .
Finally , the journal also tries to maintain a communication platform between the science produced by the membership of ESTRO and therefore it brings papers frommembers in the different European countries , sometimes at the expense of ultimate scientific quality , but with the underst and ing that it is important that the entire ESTRO membership gets access and opportunity to publish in a high ranked journal .
ESTRO , the European Society for Therapeutic Radiation Oncology , or with its new name European Society for Radiation Oncology , is a scientific society .
It means that the prime aim of ESTRO is to bring to bring people together on an individual basis who have a common interest in improving the scientific conduct of radiotherapy and cancer treatment in Europe by ensuring that proper radiotherapy is available in the multidisciplinary treatment of cancer and applied with the right indication and with the most optimal technique .
One of the main aims of this endeavour was to create a platform for scientific exchange through meetings and through the establishment of a scientific journal [ 1 ] .
Thus Radiotherapy and Oncology was launched shortly after the foundation of ESTRO and has become the society ’s prime vehicle for scientific communication by serving ESTRO members through almost the entire 30 years of the society ’s existence .
The aim was to create a peer review ed high quality international journal and that aim has indeed been fulfilled . ‘ ‘
Randomised phase II trial of hyperbaric oxygen therapy in patients with chronic arm lymphoedema after radiotherapy for cancer.
BACKGROUND A non-r and omised phase II study suggested a therapeutic effect of hyperbaric oxygen ( HBO ) therapy on arm lymphoedema following adjuvant radiotherapy for early breast cancer , justifying further investigation in a r and omised trial . METHODS Fifty-eight patients with ≥ 15 % increase in arm volume after supraclavicular ± axillary radiotherapy ( axillary surgery in 52/58 patients ) were r and omised in a 2:1 ratio to  HBO ( n=38 ) or to best st and ard care ( n=20 ) . The HBO group breathed 100 % oxygen at 2.4 atmospheres absolute for 100 min on 30 occasions over 6 weeks . Primary endpoint was ipsilateral limb volume expressed as a percentage of contralateral limb volume . Secondary endpoints included fractional removal rate of radioisotopic tracer from the arm , extracellular water content , patient self- assessment s and UK SF-36 Health Survey Question naire . FINDINGS Of 53/58 ( 91.4 % ) patients with baseline assessment s , 46 had 12-month assessment s ( 86.8 % ) . Median volume of ipsilateral limb ( relative to contralateral ) at baseline was 133.5 % ( IQR 126.0 - 152.3 % ) in the control group , and 135.5 % ( IQR 126.5 - 146.0 % ) in the treatment group . Twelve months after baseline the median ( IQR ) volume of the ipsilateral limb was 131.2 % ( IQR 122.7 - 151.5 % ) in the control group and 133.5 % ( IQR 122.3 - 144.9 % ) in the treatment group . Results for the secondary endpoints were similar between r and omised groups . INTERPRETATION No evidence has been found of a beneficial effect of HBO in the treatment of arm lymphoedema following primary surgery and adjuvant radiotherapy for early breast cancer
Both journals are anchored in large scientific societies and serve basically the same medical , physical and biological community and at the same scientific level ; the two journals are in the most recent Impact Factor list ranked almost back to back , indicating an equal importance and contribution to science .
Radiotherapy and Oncology is more than a scientific journal , it also serves other purpose s such as facilitate education through ( educational ) review s and improving the st and ard of care by bringing forward guidelines for conduct of radiotherapy .
Finally , the journal also tries to maintain a communication platform between the science produced by the membership of ESTRO and therefore it brings papers frommembers in the different European countries , sometimes at the expense of ultimate scientific quality , but with the underst and ing that it is important that the entire ESTRO membership gets access and opportunity to publish in a high ranked journal .
ESTRO , the European Society for Therapeutic Radiation Oncology , or with its new name European Society for Radiation Oncology , is a scientific society .
It means that the prime aim of ESTRO is to bring to bring people together on an individual basis who have a common interest in improving the scientific conduct of radiotherapy and cancer treatment in Europe by ensuring that proper radiotherapy is available in the multidisciplinary treatment of cancer and applied with the right indication and with the most optimal technique .
One of the main aims of this endeavour was to create a platform for scientific exchange through meetings and through the establishment of a scientific journal [ 1 ] .
Thus Radiotherapy and Oncology was launched shortly after the foundation of ESTRO and has become the society ’s prime vehicle for scientific communication by serving ESTRO members through almost the entire 30 years of the society ’s existence .
The aim was to create a peer review ed high quality international journal and that aim has indeed been fulfilled . ‘ ‘